These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 6785350)

  • 1. The third component of complement: covalent attachment of a radioactive sugar to the labile binding site of C3 via the alternative pathway.
    Mann J; O'Brien R; Hostetter MK; Alper CA; Rosen FS; Babior BM
    J Immunol; 1981 Jun; 126(6):2370-2. PubMed ID: 6785350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formation of covalently linked C3-C3 dimers on IgG immune aggregates.
    Barrio E; Antón LC; Marqués G; Sánchez A; Vivanco F
    Eur J Immunol; 1991 Feb; 21(2):343-9. PubMed ID: 1999223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attachment of [35S]cysteine to the labile site of the third component of complement via the alternative pathway.
    Rutherford CJ; Alper CA; Rosen FS; Babior BM
    Clin Immunol Immunopathol; 1983 Jan; 26(1):76-82. PubMed ID: 6872338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C3 binds with similar efficiency to Fab and Fc regions of IgG immune aggregates.
    Antón LC; Ruiz S; Barrio E; Marqués G; Sánchez A; Vivanco F
    Eur J Immunol; 1994 Mar; 24(3):599-604. PubMed ID: 8125130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells.
    Mold C; Nemerow GR; Bradt BM; Cooper NR
    J Immunol; 1988 Mar; 140(6):1923-9. PubMed ID: 2831273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Covalent binding of [35S]cysteine to the labile binding site of the third component of complement: a physiological approach.
    Rutherford CJ; Jenkins DR
    Clin Immunol Immunopathol; 1985 Oct; 37(1):77-82. PubMed ID: 4028522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of C3 with antigen-antibody complexes in the process of solubilization of immune precipitates.
    Takata Y; Tamura N; Fujita T
    J Immunol; 1984 May; 132(5):2531-7. PubMed ID: 6232320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-covalently bound C3 enhances lysis of rabbit erythrocytes through the alternative pathway.
    Hidvégi T; Füst G; Rajnavölgyi E; Kulics J; Gergely J
    Immunology; 1985 Dec; 56(4):735-41. PubMed ID: 3935572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural release of covalently bound C3b from cell surfaces and the study of this phenomenon in the fluid-phase system.
    Venkatesh YP; Minich TM; Law SK; Levine RP
    J Immunol; 1984 Mar; 132(3):1435-9. PubMed ID: 6693771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An affinity for complement C3 as a possible reason for the potency of naturally occurring antibodies in mediating tissue homeostasis.
    Lutz HU; Fasler S; Stammler P
    Beitr Infusionsther; 1989; 24():193-9. PubMed ID: 2481539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
    Mayes JT; Schreiber RD; Cooper NR
    J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum.
    Gadd KJ; Reid KB
    Biochem J; 1981 May; 195(2):471-80. PubMed ID: 7316962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
    Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
    Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement.
    Pangburn MK; Müller-Eberhard HJ
    J Exp Med; 1980 Oct; 152(4):1102-14. PubMed ID: 6903192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus.
    Kostavasili I; Sahu A; Friedman HM; Eisenberg RJ; Cohen GH; Lambris JD
    J Immunol; 1997 Feb; 158(4):1763-71. PubMed ID: 9029114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody restores human alternative complement pathway activation by mouse erythrocytes rendered functionally deficient by pretreatment with pronase.
    Moore FD; Austen KF; Fearon DT
    J Immunol; 1982 Mar; 128(3):1302-6. PubMed ID: 6915957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative complement pathway-dependent ingestion of fluolite particles by human granulocytes.
    Arnaout MA; Luscinskas FW; Lionetti FJ; Alper CA; Valeri CR
    J Immunol; 1981 Jul; 127(1):278-81. PubMed ID: 6787126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of the alternative complement pathway by isolated human glomerular basement membrane.
    Williams JD; Czop JK; Abrahamson DR; Davies M; Austen KF
    J Immunol; 1984 Jul; 133(1):394-9. PubMed ID: 6373930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
    Sahu A; Kay BK; Lambris JD
    J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor-binding sites on C3 and C3b.
    Dierich MP; Bokisch VA
    J Immunol; 1977 Jun; 118(6):2145-50. PubMed ID: 864256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.